canagliflozin
AssetAlso called Canagliflozin 300 mg, JNJ-28431754, TA-7284, Teneligliptin/Canagliflozin
Fixed-dose combination of DPP-4 inhibitor teneligliptin and SGLT2 inhibitor canagliflozin to improve glycemic control
- Stage
- Approved
- Modality
- Small molecule
- Target
- SLC5A2
- 20
- Indications
- 100
- Trials
- 4
- Developers
First approved in 2011, as ChEMBL records; approved by the FDA on Mar 29, 2013 (NDA204042). 2 approvals stand. FDA
Indications
20Type 2 diabetes
Approved, FDA
Diabetic kidney disease
Approved, FDA
End-stage renal disease
Approved, FDA
17 more
In the full profile
- Target and mechanism1
- Owner and partners4
- Trials100
- Evidence for its targets2
- Competitors12
- Aging relevance3
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.